Meeting
2022 ASCO Annual Meeting
Impact of ribociclib (RIB) dose modifications (mod) on overall survival (OS) in patients (pts) with HR+/HER2- advanced breast cancer (ABC) in MONALEESA(ML)-2.
Authors
Lowell L. Hart
Florida Cancer Specialists and Research Institute, Fort Myers, FL
Lowell L. Hart , Aditya Bardia , Joseph Thaddeus Beck , Arlene Chan , Patrick Neven , Erika P. Hamilton , Joohyuk Sohn , Gabe S. Sonke , Thomas Bachelot , Laura Spring , Fabienne Le Gac , Huilin Hu , Ming Gao , Michelino De Laurentiis
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Hormone Receptor-Positive
Clinical Trial Registration Number
NCT01958021
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 1017)
DOI
10.1200/JCO.2022.40.16_suppl.1017
Abstract #
1017
Poster Bd #
395
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Ribociclib (RIB) vs. palbociclib (PAL) in patients (pts) with hormone receptor-positive/HER2-negative/HER2-enriched (HR+/HER2-/HER2-E) advanced breast cancer (ABC): A head-to-head phase III study—HARMONIA SOLTI-2101/AFT-58.
First Author: Tomás Pascual
First Author: Hope S. Rugo
Poster
2019 ASCO Annual Meeting
First-line (1L) ribociclib (RIB) plus letrozole (LET) for postmenopausal women with hormone receptor-positive (HR+), HER2- advanced breast cancer (ABC): MONALEESA-2 long-term safety results.
First Author: Joyce O'Shaughnessy
Poster
2017 ASCO Annual Meeting
Health-related quality of life (HRQoL) of postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) treated with ribociclib + letrozole: Results from MONALEESA-2.
First Author: Sunil Verma